Genetic polymorphism of cytochrome P450 enzymes in Asian populations: Focus on CYP2D6

International Journal of Clinical Pharmacology Research

Volumn 23, Issue 1, 2003, Pages 31-35

  Kitada, M ^a,b  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b 1 8 1 Inohana ^*  (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; CODEINE; CYTOCHROME P450; CYTOCHROME P450 2D6; HALOPERIDOL; MORPHINE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT;

ASIAN; CAUCASIAN; CHINESE; DEPRESSION; DRUG METABOLISM; ENZYME ACTIVITY; ETHNIC GROUP; GENETIC POLYMORPHISM; HUMAN; INDIAN; JAPAN; MENTAL DISEASE; NEGRO; PHENOTYPE; RACE DIFFERENCE; REVIEW; SCHIZOPHRENIA;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; HUMANS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0242332641     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Guengerich F.P. Characterization of human cytochrome P450 enzymes. FASEB J., 6, 745, 1997.
2. Davis M.P., Homsi J. The importance of cytochrome P450 monooxygenase CYP2D6 in palliative medicine. Support Care Cancer, 9, 442, 2001.
3. Jann M.W., Cohen L.J. Ethnicity and antidepressant pharmacogenetics. Drug Metabol. Drug Interact., 16, 39, 2000.
4. Wanwimolruk S., Bhawan S., Colville P.F., Chalcroft S.C.W. Pharmacokinetics and disposition, genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Eur. J. Clin. Pharmacol., 54, 431, 1998.
5. Roberts R., Sullivan P., Joyce P., Kennedy M.A. Rapid and comprehensive determination of cytochrome P450 CYP2D6 poor metabolizer genotypes by multiplex polymerase chain reaction. Hum. Mutat., 16, 77, 2000.
6. Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population, allele frequencies and phenotypic consequences. Am. J. Hum. Genet., 60, 284, 1997.
7. Tanaka E., Hisawa S. Clinically significant pharmacokinetic drug interactions with psychoactive drugs: Antidepressants and antipsychotics and the cytochrome P450 system. J. Clin. Pharm. Ther., 24, 7, 1999.
8. Spina E., Gitto C., Avenoso A., Campo G.M., Caputi A.P., Perucca E. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine, a prospective study. Eur. J. Clin. Pharmacol., 51, 395, 1997.
9. Kaiser R., Sezer O., Papies A., et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J. Clin. Oncol., 20, 2805, 2002.
10. De Wit R. Current position of 5HT3-antagonists and the additional value of NK1 antagonists, a new class of antiemetics. Br. J. Cancer, 88, 1823, 2003.
11. Ingelman-Sundberg M., Oscarson M., McLellan R.A. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol. Sci., 20, 342, 1999.
12. Wanwimolruk S., Patamasucon P., Lee E.J. Evidence for the polymorphic oxidation of debrisoquin in the Thai population. Br. J. Clin. Pharmacol., 29, 244, 1990.
13. Lou Y.C., Ying L., Bertilsson L., Sjoqvist F. Low frequency of slow debrisoquine hydroxylation in native Chinese population. Lancet, 2, 852, 1987.
14. Nakamura K., Goto F., Ray W.A., McAllister C.B., Jacqz E. Interethnic differences in genetic polymorphism of debrisoquine and mephytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther., 38, 402, 1985.
15. Abraham B.K., Adithan C., Kiran P.U., Asad M., Koumaravelou K. Genetic polymorphism of CYP2D6 in Karnataka and Andhra Pradesh population in India. Acta. Pharmacol. Sin., 21, 494, 2000.
16. Abraham B.K., Adithan C., Shashindran C.H., Vasu S., Alekutty N.A. Genetic polymorphism of CYP2D6 in a Keralite (South India) population. Br. J. Clin. Pharmacol., 49, 283, 2000.
17. Idle J.R., Smith R.L. The debrisoquine hydroxylation gene: a gene of multiple consequences. In: "Proceedings of the Second World Conference of Clinical Pharmacology and Therapeutics." Lemberger L., Reidenberg M.M., Washington D.C., (Eds.), Am. Soc. Pharmacol. Exp. Ther., 148, 1984.
18. Lamba V., Lamba J.K., Dilawari J.B., Kohli K.K. Genetic polymorphism of CYP2D6 in North Indian subjects. Eur. J. Clin. Pharmacol., 54, 787, 1998.
19. Mamidi R.N.V.S., Satyavageeswaran S., Vakkalanka S.V.S. et al. Polymorphism of dextromethorphan oxidation in South Indian subjects. Clin. Pharmacol. Ther., 66, 193, 1999.
20. Relling M.V., Cherrie J., Shell M.J., Petros W.P., Meyer W.H., Evans W.E. Lower prevalence of the debrisoquine oxidative poor metabolizer phenotype in American black versus white subjects. Clin. Pharmacol. Ther., 50, 308, 1991.
21. Islam S.I., Idle J.R., Smith R.L. The polymorphic 4-hydroxylation of debrisoquine in a Saudi Arabian population. Xenobiotica, 10, 819, 1980.
22. Nishida Y., Fukuda T., Yamamoto I., Azuma J. CYP2D6 genotypes in a Japanese population: Low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics, 10, 567, 2000.
23. Kubota T., Yamaura Y., Ohkawa N., Hara H., Chiba K. Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes. Br. J. Clin. Pharmacol., 50, 31, 2000.
24. Garcia-Barcelò M., Chow L.Y., Chiu H.F.K., et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population. Clin. Chem., 46, 18, 2000.
25. Bertilsson L. Geographic/interracial differences in polymorphic drug oxidation. Clin. Pharmacokinet., 29, 192, 1995.
26. Tseng C.-Y., Wang S.-L., Lai M.-D., Lai M.-L., Huang J.-D. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin. Pharmacol. Ther. 60, 177, 1996.
27. Mihara K., Suzuki A., Kondo T., et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin. Pharmacol. Ther., 65, 291, 1999.